PhD in Biology from Southeast University, founded Zhihe Biotechnology in 2016, built a radioactive drug research and development platform based on biotechnology, and laid out multiple nuclide diagnosis and treatment pipelines, rapidly growing into a leading domestic radioactive innovative drug research and development enterprise. The first rhTSH drug (recombinant human thyroid stimulating hormone) in China was launched in 2024, and several new radiopharmaceuticals are currently in the clinical stage.
Previously worked at the National Human Genome Southern Research Center and Suzhou Corning Jerry Biotechnology. Also founded Suzhou Panomike Biotechnology and served as its CEO.
Suzhou Industrial Park Science and Technology Leading Talent, Part time Professor at Zhongke Suzhou Pharmaceutical Research Institute, Secretary General of China Nuclear Drug Innovation Chain Alliance.